Cargando…

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

Detalles Bibliográficos
Autores principales:	Schavgoulidze, Anaïs, Perrot, Aurore, Cazaubiel, Titouan, Leleu, Xavier, Montes, Lydia, Jacquet, Caroline, Belhadj, Karim, Brechignac, Sabine, Frenzel, Laurent, Chalopin, Thomas, Rey, Philippe, Schiano de Collela, Jean-Marc, Dib, Mamoun, Caillot, Denis, Macro, Margaret, Fontan, Jean, Buisson, Laure, Pavageau, Luka, Roussel, Murielle, Manier, Salomon, Mohty, Mohamad, Martinet, Ludovic, Avet-Loiseau, Hervé, Corre, Jill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600097/ https://www.ncbi.nlm.nih.gov/pubmed/37880285 http://dx.doi.org/10.1038/s41408-023-00933-4

Ejemplares similares

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
por: Schavgoulidze, A., et al.
Publicado: (2022)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

3.1416 and all that
por: Davis, Philip J, et al.
Publicado: (1985)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
por: Bobin, A., et al.
Publicado: (2022)

P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).
por: Macro, Margaret, et al.
Publicado: (2023)

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
por: Macro, M., et al.
Publicado: (2022)

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma
por: Lemaitre, Léa, et al.
Publicado: (2020)

Draft Genome Sequence of Serratia sp. 1D1416
por: Alabed, Diaa, et al.
Publicado: (2019)

Complete Genome of Agrobacterium fabrum Strain 1D1416
por: Alabed, Diaa, et al.
Publicado: (2023)

1416. Nocardia beijingensis: A Rare and Unusual Cause of Intracranial Abscess
por: Chauhan, Lakshpaul, et al.
Publicado: (2019)

1416. Assessing the potential for interspecies transmission of Clostridioides difficile on dairy farms
por: Redding, Laurel, et al.
Publicado: (2020)

P1416: THE CLINICAL SPECTRUM AND PROGNOSTIC FACTORS OF ERDHEIM-CHESTER DISEASE
por: Dai, Jia-Wen, et al.
Publicado: (2023)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
por: Macro, M., et al.
Publicado: (2022)

1416. Medicare Spending on Urinary Tract Infections: A Retrospective Database Analysis
por: Sulham, Kate, et al.
Publicado: (2021)

Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416
por: Xu, Yan, et al.
Publicado: (2012)

1416. Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Interpatient Variability or Compound Instability?
por: Crass, Ryan L, et al.
Publicado: (2018)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

Survival of >20 years in a myeloma patient with an unusual combination of t(14;16) and hyperdiploidy: A case report
por: CHIM, CHOR SANG, et al.
Publicado: (2013)

P1416: DNA DAMAGE TRIGGERS A P53 INDUCED AGEING RESPONSE IN HAEMATOPOIETIC STEM CELLS
por: Wang, M., et al.
Publicado: (2022)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
por: Hulin, C., et al.
Publicado: (2022)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Das BRCA-like-Mammakarzinom profitiert von Cisplatin plus Veliparib; Ergebnisse der S1416-Phase-II-Studie
por: Hintelmann, Katharina, et al.
Publicado: (2023)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
por: Narita, T, et al.
Publicado: (2015)

1416. The Economic Burden of Adverse Events Requiring Acute Care Services from Outpatient Parenteral Antibiotic Therapy (OPAT) Treatment
por: Rodriguez, Mauricio, et al.
Publicado: (2022)

Expressed fusion gene landscape and its impact in multiple myeloma
por: Cleynen, A., et al.
Publicado: (2017)

Corrigendum to “The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients” [Kidney Int. Rep. 2020 1416–1421]
por: Xu, Xin, et al.
Publicado: (2021)

1416. Walk a Mile in Someone Else’s Shoes: Navigating the Complexity of Daily Environmental Cleaning – A Quality Improvement Pilot Project
por: McKinley, Linda, et al.
Publicado: (2023)

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2022)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0q2a563r1bvgjkb6org2s5cgu0